Marsollier Laurent, Prévot Ghislaine, Honoré Nadine, Legras Pierre, Manceau Anne Lise, Payan Christopher, Kouakou Henri, Carbonnelle Bernard
Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU, 49033 Angers Cedex 01, France.
Int J Antimicrob Agents. 2003 Dec;22(6):562-6. doi: 10.1016/s0924-8579(03)00240-1.
The effectiveness of rifampicin (RIF), amikacin (AMK) and their combination were estimated in the treatment of mice experimentally infected by Mycobacterium ulcerans and the risk of relapse after the treatment was evaluated. After 7 weeks of treatment with RIF or with the combination of AMK/RIF and 8 weeks with AMK alone, no viable bacilli were found in the infected tissues and these remained uninfected during the following 6 months. Among the mice treated with AMK alone, three mice relapsed, but the minimal inhibitory concentration of AMK for these isolates remained unchanged. With RIF alone, two mice relapsed and the minimal inhibitory concentration of these isolated strains was higher. However, with all the mice treated with both RIF and AMK, no relapse was observed.
评估了利福平（RIF）、阿米卡星（AMK）及其联合用药在治疗实验性感染溃疡分枝杆菌小鼠中的有效性，并评估了治疗后复发的风险。用RIF或AMK/RIF联合治疗7周，单独用AMK治疗8周后，在感染组织中未发现活菌，且在接下来的6个月内这些组织仍未被感染。在单独用AMK治疗的小鼠中，有3只小鼠复发，但AMK对这些分离株的最低抑菌浓度保持不变。单独使用RIF时，有2只小鼠复发，这些分离菌株的最低抑菌浓度更高。然而，在用RIF和AMK联合治疗的所有小鼠中，未观察到复发。
